#SunPharma's shares fall after it announces it'll buy #ConcertPharmaceuticals for $576 million.

#SunPharma enters into an exclusive distribution, licence, & supply agreement with Philogen to commercialise Nidlegy in EU, Australia & New Zealand

Sun Pharma (#SunPharma_Live) gets approval from Health Canada for Absorica LD, an #acne drug

#1QWithCNBCTV18 | #SunPharma will report its #Q1 earnings today. The street expects the pharma giant to report 8% growth in profit. Growth to be led by specialty portfolio in US & other international markets https://t.co/IHFSTRmZXC

#1QWithCNBCTV18 | #SunPharma reports #Q1 earnings

⭕️ Net profit at ₹2,022.5 cr vs CNBC-TV18 poll of ₹2,090.4 cr https://t.co/7V5jTbEJLL

#1QWithCNBCTV18 | #SunPharma report #Q1 earnings

▶️One-time loss at ₹323 cr

▶️Other income at ₹204.4 cr vs ₹2.1 cr (YoY) https://t.co/KqLPNwnBB8

#OnCNBCTV18 | Taro Board has appointed a special committee on Sun's offer. Not giving specific guidance on speciality business. Committed to #FY24 #guidance of high-single digit growth in revenue, says CS Muralidharan of #SunPharma

#1QWithCNBCTV18 https://t.co/ayJ1dWGXDh

Sun Pharma #FY24Outlook | Company expect high-single-digit consolidated topline growth for #FY24

#SunPharma https://t.co/uF7qEERZEc

#SunPharma subsidiary #TaroPharma reported a 12.5% jump in its overall sales for the January-March quarter to $164.9 million, writes @ekta_batra

▶️Gross profit up 16% at $87.4 million vs $75.7 million (YoY)
▶️Operating income down 5% at $8.8 million vs $9.3 million (YoY)
▶️Net income at $15.1 million vs $6.9 million (YoY)

#SunPharma recovers in trade, stock rises 2% from lows

#SunPharma & Israel-based Moebius Medical granted US FDA Fast Track designation (FTD) to MM-II (Large Liposomes of DPPC and DMPC), used for the treatment of osteoarthritis knee pain